What is the outcome of the Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI) trial?
The Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI) trial found that tenecteplase-facilitated percutaneous coronary intervention (PCI) was associated with a shorter door-to-balloon time and a lower 30-day mortality rate compared to primary PCI alone. However, there was no difference in the rate of major adverse cardiovascular events at one year among those who received tenecteplase-facilitated PCI compared to primary PCI alone. 